Floatz logo

Tuvonralimab

Secondary Malignant Neoplasm of Liver

Peking University Cancer Hospital & InstitutePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Secondary Malignant Neoplasm of Liver cohort.

Asset / SponsorPhaseRating
Eloxatin
Peking University Cancer Hospital & Institute
Phase 2CCC
Iparomlimab
Peking University Cancer Hospital & Institute
Phase 2CCC
Capecitabine
Peking University Cancer Hospital & Institute
Phase 2CCC
Yttrium-90
University of Minnesota
N/AD

Same molecule, other indications

Tuvonralimab is also rated in:

CTLA-4Dormant
BB
Indicative ·
70 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
autoimmune pulmonary disease due to PD-1 deficiencyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →